177 related articles for article (PubMed ID: 27166975)
1. Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers.
Tkáč I; Gotthardová I
Pharmacogenomics; 2016 May; 17(7):795-804. PubMed ID: 27166975
[TBL] [Abstract][Full Text] [Related]
2. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.
't Hart LM; Fritsche A; Nijpels G; van Leeuwen N; Donnelly LA; Dekker JM; Alssema M; Fadista J; Carlotti F; Gjesing AP; Palmer CN; van Haeften TW; Herzberg-Schäfer SA; Simonis-Bik AM; Houwing-Duistermaat JJ; Helmer Q; Deelen J; Guigas B; Hansen T; Machicao F; Willemsen G; Heine RJ; Kramer MH; Holst JJ; de Koning EJ; Häring HU; Pedersen O; Groop L; de Geus EJ; Slagboom PE; Boomsma DI; Eekhoff EM; Pearson ER; Diamant M
Diabetes; 2013 Sep; 62(9):3275-81. PubMed ID: 23674605
[TBL] [Abstract][Full Text] [Related]
3. Association between variants in
Kyriakidou A; Kyriazou AV; Koufakis T; Vasilopoulos Y; Avramidis I; Baltagiannis S; Goulis DG; Kotsa K
Postgrad Med; 2024 Mar; 136(2):218-225. PubMed ID: 38453649
[TBL] [Abstract][Full Text] [Related]
4. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
5. The journey to understanding incretin systems: Theory, practice and more theory.
Yabe D; Kuwata H; Seino Y
J Diabetes Investig; 2019 Sep; 10(5):1171-1173. PubMed ID: 31361402
[TBL] [Abstract][Full Text] [Related]
6. [Modulation of the incretin effect in the treatment of diabetes].
Vidal J
Med Clin (Barc); 2014 Sep; 143 Suppl 2():8-11. PubMed ID: 25437459
[TBL] [Abstract][Full Text] [Related]
7. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
8. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
9. Incretins: Beyond type 2 diabetes.
Dandona P; Ghanim H; Chaudhuri A
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():59-67. PubMed ID: 29364583
[TBL] [Abstract][Full Text] [Related]
10. Incretin therapy and its effect on body weight in patients with diabetes.
Lind M
Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
[TBL] [Abstract][Full Text] [Related]
11. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
Grunberger G
J Diabetes; 2013 Sep; 5(3):241-53. PubMed ID: 23489968
[TBL] [Abstract][Full Text] [Related]
12. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
[TBL] [Abstract][Full Text] [Related]
13. Incretin based therapies for type 2 diabetes mellitus.
Ghosh S; Collier A; Elhadd T; Malik I
J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
[TBL] [Abstract][Full Text] [Related]
14. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
15. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
16. GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?
Scheen AJ
Ann Endocrinol (Paris); 2013 Dec; 74(5-6):515-22. PubMed ID: 23570814
[TBL] [Abstract][Full Text] [Related]
17. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
18. Incretin-based treatment of diabetes and cardiovascular complications.
Haluzík M
Vnitr Lek; 2020; 66(2):74-80. PubMed ID: 32942880
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of novel glucose-lowering drugs.
Rathmann W; Bongaerts B
Diabetologia; 2021 Jun; 64(6):1201-1212. PubMed ID: 33594477
[TBL] [Abstract][Full Text] [Related]
20. A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins.
Javorský M; Gotthardová I; Klimčáková L; Kvapil M; Židzik J; Schroner Z; Doubravová P; Gala I; Dravecká I; Tkáč I
Diabetes Obes Metab; 2016 Sep; 18(9):941-4. PubMed ID: 27160388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
